| Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease NV Casteele, M Ferrante, G Van Assche, V Ballet, G Compernolle, ... Gastroenterology 148 (7), 1320-1329. e3, 2015 | 947 | 2015 |
| Antibody response to infliximab and its impact on pharmacokinetics can be transient NV Casteele, A Gils, S Singh, L Ohrmund, S Hauenstein, P Rutgeerts, ... Official journal of the American College of Gastroenterology| ACG 108 (6 …, 2013 | 413 | 2013 |
| JAK–STAT pathway targeting for the treatment of inflammatory bowel disease A Salas, C Hernandez-Rocha, M Duijvestein, W Faubion, D McGovern, ... Nature reviews Gastroenterology & hepatology 17 (6), 323-337, 2020 | 406 | 2020 |
| American Gastroenterological Association Institute technical review on the role of therapeutic drug monitoring in the management of inflammatory bowel diseases NV Casteele, H Herfarth, J Katz, Y Falck-Ytter, S Singh Gastroenterology 153 (3), 835-857. e6, 2017 | 322 | 2017 |
| The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease NV Casteele, R Khanna, BG Levesque, L Stitt, GY Zou, S Singh, ... Gut 64 (10), 1539-1545, 2015 | 322 | 2015 |
| consensus statements on therapeutic drug monitoring of anti‐tumour necrosis factor therapy in inflammatory bowel diseases N Mitrev, N Vande Casteele, CH Seow, JM Andrews, SJ Connor, ... Alimentary pharmacology & therapeutics 46 (11-12), 1037-1053, 2017 | 286* | 2017 |
| Appropriate therapeutic drug monitoring of biologic agents for patients with inflammatory bowel diseases K Papamichael, AS Cheifetz, GY Melmed, PM Irving, NV Casteele, ... Clinical Gastroenterology and Hepatology 17 (9), 1655-1668. e3, 2019 | 279 | 2019 |
| Obesity and response to anti-tumor necrosis factor-α agents in patients with select immune-mediated inflammatory diseases: a systematic review and meta-analysis S Singh, A Facciorusso, AG Singh, NV Casteele, A Zarrinpar, LJ Prokop, ... PLoS One 13 (5), e0195123, 2018 | 270 | 2018 |
| Role for therapeutic drug monitoring during induction therapy with TNF antagonists in IBD: evolution in the definition and management of primary nonresponse K Papamichael, A Gils, P Rutgeerts, BG Levesque, S Vermeire, ... Inflammatory bowel diseases 21 (1), 182-197, 2015 | 243 | 2015 |
| Detection of infliximab levels and anti‐infliximab antibodies: a comparison of three different assays N Vande Casteele, DJ Buurman, MGG Sturkenboom, JH Kleibeuker, ... Alimentary pharmacology & therapeutics 36 (8), 765-771, 2012 | 233 | 2012 |
| Withdrawal of immunomodulators after co-treatment does not reduce trough level of infliximab in patients with Crohn’s disease D Drobne, P Bossuyt, C Breynaert, T Cattaert, NV Casteele, ... Clinical Gastroenterology and Hepatology 13 (3), 514-521. e4, 2015 | 221* | 2015 |
| Primary non-response to tumor necrosis factor antagonists is associated with inferior response to second-line biologics in patients with inflammatory bowel diseases: a … S Singh, J George, BS Boland, N Vande Casteele, WJ Sandborn Journal of Crohn's and Colitis 12 (6), 635-643, 2018 | 204 | 2018 |
| A panel to predict long-term outcome of infliximab therapy for patients with ulcerative colitis MT Arias, NV Casteele, S Vermeire, AB van Overstraeten, T Billiet, F Baert, ... Clinical Gastroenterology and Hepatology 13 (3), 531-538, 2015 | 201 | 2015 |
| Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial G Van Assche, S Vermeire, V Ballet, F Gabriels, M Noman, G D'Haens, ... Gut 61 (2), 229-234, 2012 | 178 | 2012 |
| Infliximab concentration thresholds during induction therapy are associated with short-term mucosal healing in patients with ulcerative colitis K Papamichael, T Van Stappen, NV Casteele, A Gils, T Billiet, S Tops, ... Clinical Gastroenterology and Hepatology 14 (4), 543-549, 2016 | 175 | 2016 |
| Early trough levels and antibodies to infliximab predict safety and success of reinitiation of infliximab therapy F Baert, D Drobne, A Gils, NV Casteele, S Hauenstein, S Singh, S Lockton, ... Clinical Gastroenterology and Hepatology 12 (9), 1474-1481. e2, 2014 | 162 | 2014 |
| Characteristics of Skin Lesions Associated With Anti–Tumor Necrosis Factor Therapy in Patients With Inflammatory Bowel Disease: A Cohort Study I Cleynen, W Van Moerkercke, T Billiet, P Vandecandelaere, ... Annals of internal medicine 164 (1), 10-22, 2016 | 138 | 2016 |
| The emerging role of histologic disease activity assessment in ulcerative colitis RK Pai, V Jairath, NV Casteele, F Rieder, CE Parker, GY Lauwers Gastrointestinal endoscopy 88 (6), 887-898, 2018 | 132 | 2018 |
| Clinical pharmacokinetics and pharmacodynamics of infliximab in the treatment of inflammatory bowel disease A Hemperly, N Vande Casteele Clinical Pharmacokinetics 57, 929-942, 2018 | 129 | 2018 |
| Pharmacokinetics of anti‐TNF monoclonal antibodies in inflammatory bowel disease: adding value to current practice N Vande Casteele, A Gils The Journal of Clinical Pharmacology 55 (S3), S39-S50, 2015 | 128 | 2015 |
William SandbornUniversity of California San DiegoVerified email at ucsd.edu
